33 research outputs found

    Analytical aspects of the automated CKMB1,2 and CKMM1,2,3 isoform determination and its relation to other biochemical markers

    No full text
    The automated (CK)MB1,2/MM1,2,3 isoform measurement, based on electrophoresis, has been simplified to the point that it has become possible to perform this analysis on a 24-h routine basis. We studied analytical aspects of this analysis and its clinical relevance in relation to other biochemical markers (CK total, CKMB activity, CKMB mass, myoglobin, Troponin I and Troponin T) in patients with acute myocardial infarction (AMI), patients with unstable angina pectoris (UAP), and healthy donors. Furthermore, the additional significance of the analysis was evaluated in patients with clinically unexpected, raised CKMB/CK total activities. The storage of serum at 4 degrees C does not influence the MB2/MB1 ratios, whereas storage at 20 degrees C changes them significantly. MM3/MM1 and normal MB2/MB1 ratios show lower coefficients of variation than increased MB2/MB1 ratios. Between 2 and 30 h after myocardial tissue damage, AMI patients showed a characteristic change in CK isoform patterns. At a mean time of 3.6 h after the onset of symptoms we found raised MB2/MB1 ratios in 94% of these patients. With the information of the CK isoform analysis unexpected abnormal CK activities could be explained by CK macro enzymes (Ig-bound and mitochondrial), insufficient CE; clearance capacity, enzyme activities 4 h after (re-)infarction, and raised CK activity 15 h after skeletal muscle damage. We conclude that the CK isoforms are relatively simply to assess; they are adequate tools with which to indicate the CK kinetics over a period lasting between 2 and 30 h after tissue damage with a single blood sample and a single analysis; the CK isoform analysis has additional value in explaining inappropriate CKMB/CK total activities, and the MB2/MB1 ratios show to be one of the best early parameters for discriminating patients with AMI on admission to hospital

    Implications of automated creatine kinase (CK)-MM1,2,3/CK-MB1,2 isoform analysis as an early marker for the detection of myocardial tissue damage

    No full text
    Measurement of creatine kinase (CK) isoforms enables the clinician to detect myocardial tissue damage at an early stage after myocardial infarction. According to the manufacturer's specifications, it should be possible to perform CK isoform analysis automatically using the new Cardio Rep(TM) analyser. In order to investigate the suitability of this new analyser we measured the CK MM1-3, and CK MB1 and 2 isoform patterns, firstly in 30 patients with acute myocardial infarction (AMI), for whom total CK and CK-MB levels were ordered, and secondly in 23 patients with chest pain suspected as having AMI (n = 11) or with unstable angina pectoris (UAP) (n = 12). The total time for analysis, including 5 min pre- and 10 min post-analyser run time, was found to be 40 min. For elevated MB2/MB1 ratios there is a discrepancy between the MB2/MB1 ratios determined from the densitometric scans concerning the surface and the peak height ratios. The MB2/MB1 ratios of the studied AMI patients exceeded the upper reference limits approximately 2 h after the onset of symptoms, whereas the CK-MB and total CK levels increased after about 6 h. The MB2/MB1 ratios from the patients with UAP were either below the detection limit or these patients could be discriminated from patients with AMI when low CK-MB and total CK levels were considered in conjunction. From our results we conclude that assessment of CK isoforms can be performed relatively simply with the new analyser within 40 min. However, for reliable calculation of the MB2/MB1 ratios, the curve monitoring of the MB2-MB1 densitometric scans should be improved. The CK isoforms are useful as an early marker for AMI as their reference interval is already exceeded approximately 2 h after an AMI. Moreover, CK isoform analysis might prove to be useful in discriminating at an early stage between AMI and other causes of chest pain. This could decrease the number of patients with a false-positive diagnosis admitted to coronary care units, resulting in a reduction of costs
    corecore